Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 495-501

  Jenkins, Molly H ^a   Steinberg, Shannon M ^a   Alexander, Matthew P ^a   Fisher, Jan L ^a   Ernstoff, Marc S ^a,b   Turk, Mary Jo ^a   Mullins, David W ^a   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, MOUSE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TUMOR PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL DIVISION; CROSS BREEDING; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; MALE; MISSENSE MUTATION; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; POINT MUTATION; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CROSSES, GENETIC; FEMALE; INDOLES; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MUTATION, MISSENSE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84898888803     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12220     Document Type: Article

References (35)

1. Ashley, M.P., and Kotlarski, I. (1986). In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells. Cell. Immunol. 101, 156-167.
2. Balch, C.M., Soong, S.-J., and Atkins, M.B. et al. (2004). An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 54, 131-149; quiz 182-4.
3. Bhowmick, N.A., Neilson, E.G., and Moses, H.L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337.
4. Blackburn, J.S., Rhodes, C.H., Coon, C.I., and Brinckerhoff, C.E. (2007). RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 67, 10849-10858.
5. Blackburn, J.S., Liu, I., Coon, C.I., and Brinckerhoff, C.E. (2009). A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 28, 4237-4248.
6. Boni, A., Cogdill, A.P., and Dang, P. et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219.
7. Chapman, P.B., Hauschild, A., and Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England J. Med. 364, 2507-2516.
8. Croteau, W., Jenkins, M.H., Ye, S., Mullins, D.W., and Brinckerhoff, C.E. (2012). Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J. Cell. Physiol. 228, 773-780.
9. Dankort, D., Curley, D.P., and Cartlidge, R.A. et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
10. Dhomen, N., Reis-Filho, J.S., and da Rocha Dias, S. et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
11. Eberle, J., Wagner, M., and Macneil, S. (1998). Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro. Pigment Cell Res. 11, 134-142.
12. Eck, S.M., Blackburn, J.S., Schmucker, A.C., Burrage, P.S., and Brinckerhoff, C.E. (2009). Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J. Autoimmun. 33, 214-221.
13. Frederick, D.T., Piris, A., and Cogdill, A.P. et al. (2013). BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231.
14. Herlyn, M., and Fukunaga-Kalabis, M. (2010). What is a good model for melanoma? J. Invest. Dermatol. 130, 911-912.
15. Hooijkaas, A., Gadiot, J., Morrow, M., Stewart, R., Schumacher, T., and Blank, C.U. (2012a). Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 1, 609-617.
16. Hooijkaas, A.I., Gadiot, J., van der Valk, M., Mooi, W.J., and Blank, C.U. (2012b). Targeting BRAFV600E in an inducible murine model of melanoma. Am. J. Pathol. 181, 785-794.
17. Huntington, J.T., Shields, J.M., and Der, C.J. et al. (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem. 279, 33168-33176.
18. Joseph, E.W., Pratilas, C.A., and Poulikakos, P.I. et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908.
19. Kawakami, Y. (1994). Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458-6462.
20. Khalili, J.S., Liu, S., and Rodríguez-Cruz, T.G. et al. (2012). Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin. Cancer Res 18, 5329-5340.
21. Knight, D.A., Ngiow, S.F., and Li, M. et al. (2013). Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Investig. 123, 1371-1381.
22. Koya, R.C., Mok, S., and Otte, N. et al. (2012). BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 192, 3928-3937.
23. Lee, J.-H., Choi, J.-W., and Kim, Y.-S. (2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776-784.
24. Leveson, S.H., Howell, J.H., Paolini, N.S., Tan, M.H., Holyoke, E.D., and Goldrosen, M.H. (1979). Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance. Cancer Res. 39(2 Pt 2), 582-586.
25. Long, G.V., Menzies, A.M., and Nagrial, A.M. et al. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
26. Marsh, T., Pietras, K., and McAllister, S.S. (2013). Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 1832, 1070-1078.
27. Menzies, A.M., Haydum, L.E., and Visintin, L. et al. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249.
28. Overwijk, W.W., Theoret, M.R., and Finkelstein, S.E. et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells. J. Exp. Med. 198, 569-580.
29. Rubinstein, J.C., Sznol, M., and Pavlick, A.C. et al. (2010). Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67.
30. Smalley, K.S.M., Lioni, M., and Herlyn, M. (2005). Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev. Anticancer Ther. 5, 1069-1078.
31. Straussman, R., Morikawa, T., and Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
32. Tsai, J., Lee, J.T., and Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046.
33. Vultur, A., Villanueva, J., and Herlyn, M. (2011). Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin. Cancer Res. 17, 1658-1663.
34. Yamshchikov, G.V., Mullins, D.W., and Chang, C. et al. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174, 6863-6871.
35. Yang, H., Higgins, B., and Kolinsky, K. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527.